Immunotherapeutic Approaches in Head and Neck Squamous Cell Carcinoma

Immunotherapy has transformed the treatment landscape for head and neck squamous cell carcinoma (HNSCC) by harnessing the patient’s own immune system to recognise and eradicate tumour cells. Central to current practice are immune checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 pathways, which reinvigorate exhausted T cells within the tumour microenvironment. Beyond checkpoint blockade, strategies include adoptive cell transfer—where T cells are expanded or genetically modified ex vivo before reinfusion—therapeutic cancer vaccines designed to stimulate antigen-specific responses, and oncolytic viruses that selectively infect malignant cells while promoting local immune activation. Combination regimens, for example pairing checkpoint inhibitors with radiotherapy or novel immune modulators, aim to overcome primary resistance and extend benefit to a broader patient population. Biomarker development, including assessment of tumour mutational burden, PD-L1 expression on both tumour and immune cells, and immune gene signatures, plays an increasingly important role in patient selection and monitoring. Taken together, these approaches offer the prospect of durable control in recurrent or metastatic HNSCC and are driving ongoing trials that seek to refine efficacy, manage toxicity and personalise therapy.

Research from Nature Portfolio

Analyses of PD-L1 expression in a large cohort of resected HNSCC specimens revealed that high PD-L1 on tumour-infiltrating immune cells, but not on tumour cells, was independently associated with improved relapse-free and overall survival. Transcriptomic profiling demonstrated enrichment of effector T-cell markers in immune cell–high PD-L1 cases, suggesting an adaptive interferon-γ–mediated mechanism. These findings underscore the importance of assessing both cellular compartments when using PD-L1 as a prognostic biomarker and in guiding checkpoint blockade therapy.

Immunotherapeutic Approaches in Head and Neck Squamous Cell Carcinoma publication trend

The graph below shows the total number of articles in immunotherapeutic approaches in head and neck squamous cell carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibition: Therapies that block regulatory receptors such as PD-1 or CTLA-4 on T cells, preventing inhibitory signalling and restoring antitumour activity.

PD-1/PD-L1: Programmed cell death protein 1 and its ligand; an inhibitory axis that downregulates T-cell function when engaged in the tumour microenvironment.

CTLA-4: Cytotoxic T-lymphocyte–associated antigen 4, an immune checkpoint receptor restricting early T-cell activation and proliferation.

Adoptive cell transfer: A treatment modality in which autologous or genetically engineered T cells are expanded ex vivo and reinfused to target tumour antigens.

Tumour microenvironment (TME): The complex milieu surrounding cancer cells, including stromal cells, immune infiltrates and signaling molecules that influence tumour growth and treatment response.

Tumour mutational burden (TMB): The total number of somatic mutations per coding region of a tumour genome, used as a predictive biomarker for immunotherapy efficacy.

Tumour-infiltrating lymphocytes (TILs): Immune cells, predominantly T cells, present within tumour tissue, indicative of the host immune response to cancer.

References

1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Journal for ImmunoTherapy of Cancer (2019).
2. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports (2016).
3. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. Journal of Clinical Investigation (2023).
4. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. International Journal of Oral Science (2020).
5. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. British Journal of Cancer (2019).